Akebia Therapeutics IncQ) expected to post a loss of 2 cents a share - Earnings Preview
Akebia Therapeutics IncQ) is anticipated to report a loss of 2 cents per share, with a projected 8.2% increase in quarterly revenue to $47.237 million for the period ending June 30, 2025. Analysts maintain a "strong buy" rating, with a median 12-month price target of $7.00, reflecting a 46.3% upside from the last closing price of $3.76. The earnings estimates have remained unchanged over the past three months, with previous quarterly performances showing mixed results against estimates.
- Akebia Therapeutics Inc (AKBA.OQ) (AKBA.O) is expected to
show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
- The Cambridge Massachusetts-based company is expected to report a 8.2% increase in revenue to $47.237 million from $43.65 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
- LSEG’s mean analyst estimate for Akebia Therapeutics Inc is for a loss of 2 cents per share.
- The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 5 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts was unchanged in the last three months.
- Wall Street’s median 12-month price target for Akebia Therapeutics Inc is $7.00, about 46.3% above its last closing price of $3.76 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -0.03 -0.04 0.03 Beat 166.7
Dec. 31 2025 -0.09 -0.08 -0.10 Missed -25
Sep. 30 2024 -0.07 -0.06 -0.10 Missed -57.9
Jun. 30 2024 -0.05 -0.05 -0.04 Beat 25
Mar. -0.08 -0.08 -0.09 Missed -17.4
31 2024
Dec. 31 2023 -0.04 -0.04 0.00 Beat 100
Sep. 30 2023 -0.07 -0.08 -0.08 Met 5.9
Jun. 30 2023 -0.02 -0.02 -0.06 Missed -140
This summary was machine generated August 5 at 13:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
